Get the Stockscreener App
13.78
4.57%
-0.66
After Hours:
13.78
Surgery Partners Inc stock is traded at $13.78, with a volume of 1.04M.
It is down -4.57% in the last 24 hours and up +6.74% over the past month.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
See More
Previous Close:
$14.44
Open:
$14.4
24h Volume:
1.04M
Relative Volume:
0.63
Market Cap:
$1.80B
Revenue:
$3.34B
Net Income/Loss:
$97.10M
P/E Ratio:
-23.16
EPS:
-0.595
Net Cash Flow:
$208.00M
1W Performance:
-2.96%
1M Performance:
+6.74%
6M Performance:
-12.48%
1Y Performance:
-37.82%
1-Day Range:
$13.75
$14.44
1-Week Range:
$13.75
$15.17
52-Week Range:
$11.41
$24.18
Surgery Partners Inc Stock (SGRY) Company Profile
Name
Surgery Partners Inc
Sector
Industry
Phone
615-234-5900
Address
340 SEVEN SPRINGS WAY, BRENTWOOD, TN
Compare SGRY vs HCA, THC, DVA, FMS, EHC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGRY
Surgery Partners Inc
|
13.78 | 1.89B | 3.34B | 97.10M | 208.00M | -0.595 |
HCA
Hca Healthcare Inc
|
426.37 | 96.54B | 76.39B | 7.81B | 7.93B | 29.08 |
THC
Tenet Healthcare Corp
|
191.68 | 16.40B | 21.46B | 2.65B | 3.35B | 19.23 |
DVA
Davita Inc
|
198.93 | 12.75B | 13.64B | 1.05B | 1.31B | 9.555 |
FMS
Fresenius Medical Care Ag Adr
|
21.76 | 11.83B | 22.18B | 1.36B | 2.00B | 1.9216 |
EHC
Encompass Health Corp
|
104.82 | 10.53B | 6.07B | 793.80M | 464.40M | 5.9914 |
Surgery Partners Inc Stock (SGRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Resumed | JP Morgan | Neutral |
| Jul-28-25 | Resumed | BofA Securities | Buy |
| Dec-16-24 | Initiated | BofA Securities | Buy |
| Oct-14-24 | Initiated | UBS | Buy |
| Oct-11-24 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-28-24 | Initiated | Macquarie | Outperform |
| Mar-06-24 | Initiated | Barclays | Equal Weight |
| Nov-14-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Jun-02-23 | Upgrade | BofA Securities | Neutral → Buy |
| May-12-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-23-22 | Reiterated | RBC Capital Mkts | Outperform |
| Jun-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-10-22 | Resumed | Citigroup | Buy |
| Nov-30-21 | Initiated | Barclays | Overweight |
| Nov-29-21 | Upgrade | Stifel | Hold → Buy |
| Nov-01-21 | Initiated | JP Morgan | Neutral |
| Oct-18-21 | Initiated | SVB Leerink | Outperform |
| Sep-10-21 | Initiated | Cowen | Market Perform |
| Jun-23-21 | Resumed | Stifel | Hold |
| Sep-17-20 | Reiterated | The Benchmark Company | Buy |
| Apr-27-20 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-03-20 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-14-20 | Reiterated | The Benchmark Company | Buy |
| Nov-16-18 | Initiated | UBS | Neutral |
| Sep-18-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jun-28-18 | Upgrade | Stifel | Sell → Hold |
| Jan-30-18 | Reiterated | The Benchmark Company | Buy |
| Nov-01-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-09-17 | Downgrade | KeyBanc Capital Mkts | Overweight → Sector Weight |
| Aug-09-17 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Aug-09-17 | Downgrade | Stifel | Hold → Sell |
| Apr-24-17 | Reiterated | Stifel | Hold |
| Mar-10-17 | Downgrade | Stifel | Buy → Hold |
| Jan-31-17 | Initiated | The Benchmark Company | Buy |
| Jun-10-16 | Initiated | KeyBanc Capital Mkts | Overweight |
| Mar-14-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-27-15 | Initiated | Stifel | Buy |
| Oct-26-15 | Initiated | RBC Capital Mkts | Outperform |
| Oct-26-15 | Initiated | Raymond James | Strong Buy |
View All
Surgery Partners Inc Stock (SGRY) Latest News
Ambulatory Surgical Centers Market to Reach US$ 162.13 Billion - openPR.com
A Quick Look at Today's Ratings for Surgery Partners(SGRY.US), With a Forecast Between $16.25 to $21 - Moomoo
MSN Money - MSN
A Look At Surgery Partners (SGRY) Valuation After Reaffirmed Guidance And Positive First Quarter Results - Sahm
Is Surgery Partners’ (SGRY) Q1 Beat And Reaffirmed 2026 Outlook Altering The Investment Case? - Yahoo Finance
Number of shareholders of Surgery Partners, Inc. – LSX:A14YWP - TradingView
Stronger Q1 Results And Reaffirmed Outlook Might Change The Case For Investing In Surgery Partners (SGRY) - simplywall.st
Surgery Partners SGRY Q1 2026 Earnings Transcript - AOL.com
Deals tracker: Cross Country Healthcare to be acquired for $437M - Modern Healthcare
Surgery Partners price target raised to $17 from $15 at Jefferies - TipRanks
Jefferies Maintains Surgery Partners(SGRY.US) With Buy Rating, Raises Target Price to $17 - Moomoo
FMR LLC holds 2.19M SGRY shares (1.7%) — Surgery Partners (NYSE: SGRY) - Stock Titan
Surgery Partners Q1 2026 Earnings Call Transcript - Sahm
Surgery Partners, Inc. (NASDAQ:SGRY) Q1 2026 Earnings Call Transcript - Insider Monkey
Surgery Partners Q1 2026 earnings preview - MSN
KeyBanc Maintains Surgery Partners(SGRY.US) With Hold Rating - Moomoo
SGRY Q1 Deep Dive: Stable Margins and Physician Recruitment Offset Volume Headwinds - The Globe and Mail
Surgery Partners Q1 2026 slides: revenue beats amid regulatory pressures By Investing.com - Investing.com South Africa
Surgery Partners Balances Growth Ambitions With Rising Headwinds - TipRanks
Surgery Partners outlines 2026 revenue of $3.35B-$3.45B and adjusted EBITDA of at least $530M as portfolio optimization targets mid-2026 announcement - MSN
Surgery Partners : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Surgery Partners Q1 Earnings Call Highlights - Yahoo Finance
Surgery Partners (SGRY) Q1 2026 revenue rises as net loss narrows - Stock Titan
Surgery Partners Releases Q1 2026 Financial Results - AlphaStreet
Surgery Partners | 8-K: SURGERY PARTNERS, INC. ANNOUNCES FIRST QUARTER 2026 RESULTS REAFFIRMS FULL YEAR 2026 GUIDANCE - Moomoo
Surgery Partners (SGRY) reports Q1 loss, tops revenue estimates - MSN
Surgery Partners Q1 2026 slides: revenue beats amid regulatory pressures - Investing.com India
Surgery Partners Narrows Slips to a Loss in Q1 2026, Beats Estimates - AlphaStreet
Earnings call transcript: Surgery Partners Q1 2026 earnings beat forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Surgery Partners Q1 2026 earnings beat forecasts - Investing.com UK
Surgery Partners Q1 Swings to Adjusted Net Loss, Revenue Rises; Full-Year 2026 Revenue Guidance Reaffirmed - marketscreener.com
Surgery Partners reports Q1 adjusted EPS (3c), consensus (14c) - TipRanks
Surgery Partners, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Surgery Partners (SGRY) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Surgery Partners, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:SGRY) 2026-05-05 - Seeking Alpha
Surgery Partners backs FY26 revenue view $3.35B-$3.45B, consensus $3.41B - TipRanks
Surgery Partners Inc (NASDAQ:SGRY) Q1 2026 Results Show Narrower Loss and Revenue Beat, But Stock Dips - ChartMill
Q1 2026 Surgery Partners Inc Earnings Call Transcript - GuruFocus
Earnings Flash (SGRY) Surgery Partners, Inc. Posts Q1 Adjusted Loss $0.03 per Share, vs. FactSet Est of $-0.12 - marketscreener.com
Earnings Flash (SGRY) Surgery Partners, Inc. Reports Q1 Revenue $810.9M, vs. FactSet Est of $797.7M - marketscreener.com
Surgery Partners stock rises 2% on beating estimates, reaffirming 2026 guidance By Investing.com - Investing.com South Africa
Surgery Partners stock rises 2% on beating estimates, reaffirming 2026 guidance - Investing.com
SURGERY PARTNERS ($SGRY) Releases Q1 2026 Earnings - Quiver Quantitative
Surgery Partners Inc has recently announced that its financial outlook for fiscal year 2026 remains stable. - Bitget
Surgery Partners, Inc. Announces First Quarter 2026 Results Reaffirms Full Year 2026 Guidance - The Manila Times
Surgery Partners: Q1 Earnings Snapshot - marketscreener.com
Surgery Partners Q1 results beat estimates - TradingView
Surgery Partners’s (NASDAQ:SGRY) Q1 CY2026 Sales Beat Estimates - TradingView
Short-stay surgery operator keeps 2026 forecast after $811M quarter - Stock Titan
Earnings Flash (SGRY) Surgery Partners, Inc. Posts Q1 Adjusted Loss $0.03 per Share, Vs. FactSet Est of $-0.12 - Moomoo
Surgery Partners posts Q1 revenue $810.9M, Adjusted EBITDA $102.3M; reaffirms 2026 guidance - TradingView
Surgery Partners Inc Stock (SGRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.48%
5.03%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):